Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines

Cancer Research

Volumn 58, Issue 19, 1998, Pages 4349-4357

  Mackey, John R ^a,c   Mani, Rajam S ^a   Selner, Milada ^a   Mowles, Delores ^a   Young, James D ^a   Belt, Judith A ^b   Crawford, Charles R ^b   Cass, Carol E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; GEMCITABINE; NUCLEOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MEMBRANE TRANSPORT; DRUG PROTEIN BINDING; DRUG UPTAKE; ENZYME SPECIFICITY; HUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CELL DIVISION; CELL SURVIVAL; DEOXYCYTIDINE; DIPYRIDAMOLE; DNA, COMPLEMENTARY; HELA CELLS; HUMANS; K562 CELLS; KINETICS; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; NUCLEOSIDE TRANSPORT PROTEINS; RECOMBINANT PROTEINS; THIOINOSINE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032188825     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Blackstein, M., Vogel, C. L., and Ambiner, R. Phase II study of gemcitabine in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncoi., 15: 135, 1996.
2. Carmichael, J., Possinger, K., Phillip, P., Beykirch, M., Kerr, H., Walling, J., and Harris, A. L. Advanced breast cancer: a phase II trial with gemcitabine. J. Clin. Oncol., 13: 2731-2736, 1995.
3. Pollera, C. F., Ceribelli, A., Crecco, M., and Calabresi, F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann. Oncol., 5: 182-184, 1994.
4. Lund, B., Hansen, O. P., Theilade, K., Hansen, M., and Neijt, J. P. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J. Natl. Cancer Inst., 86: 1530-1533, 1994.
5. Anderson, H., Lund, B., Bach, F., Thatcher, N., Walling, J., and Hansen, H. H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol., 12: 1821-1826, 1994.
6. Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., and Rugg, T. A. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J. Clin. Oncol., 12: 1535-1540, 1994.
7. Casper, E. S., Green, M. R., Kelsen, D. P., Heelan, R. T., Brown, T. D., Flombaum, C. D., Trochanowski, B., and Tarassoff, P. G. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine in patients with adenocarcinoma of the pancreas. Invest. New Drugs, 12: 29-34, 1994.
8. Moore, M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. Cancer (Phila.), 78: 633-638, 1996.
9. Catimel, G., Vermerken, J. B., Clavel, M., de Mulder, P., Judson, I., Sessa, C., Piccart, M., Bruntsch, U., Verweij, J., Wanders, J., Franklin, H., and Kay, S. B. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann. Oncol., 5: 543-547, 1994.
10. Heinemann, V., Hertel, L. W., Grindey, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48: 4024-4031, 1988.
11. Ruiz van Haperen, V. W., Veerman, G., Vermorken, J. B., and Peters, G. J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol., 46: 762-766, 1993.
12. Plunkett, W., Huang, P., Xu, Y. Z., Heinemann, V., Grunewald, R., and Gandhi, V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol., 22: 3-10, 1995.
13. Fink, U., Molle, B., and Daschner, H. Phase II study of gemcitabine in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 11: A507, 1992.
14. Ruiz van Haperen, V. W., Veerman, G., Eriksson, S., Boven, E., Stegmann, A. P., Hermsen, M., Vermorken, J. B., Pinedo, H. M., and Peters, G. J. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res., 54: 4138-4143, 1994.
15. Neff, T., and Blau, C. A. Forced expression of cytidine deaminase confers resistance to 1-β-D-arabinofuranosylcytosine and gemcitabine. Exp. Hematol., 24: 1340-1346, 1996.
16. Sliutz, G., Karlseder, J., Tempfer, C., Orel, L., Holzer, G., and Simon, M. M. Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. Br. J. Cancer, 74: 172-177, 1996.
17. Waud, W. R., Gilbert, K. S., Grindey, G. B., and Worzalla, J. F. Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias. Cancer Chemother. Pharmacol., 38: 178-180, 1996.
18. Cass, C. E. Nucleoside transport. In: N. H. Georgopapadakou (ed.), Drug Transport in Antimicrobial Therapy and Anticancer Therapy, pp. 403-451. New York: Marcel Dekker, 1995.
19. Griffiths, M., Beaumont, N., Yao, S. Y., Sundaram, M., Boumah, C. E., Davies, A., Kwong, F. Y., Coe, I., Cass, C. E., Young, J. D., and Baldwin, S. A. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat. Med., 3; 89-93, 1997.
20. Crawford, C. R., Patel, D. H., Naeve, C., and Belt, J. A. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. J. Biol. Chem., 273: 5288-5293, 1998.
21. Griffiths, M., Yao, S. Y. M., Abidi, F., Phillips, S. E. V., Cass, C. E., Young, J. D., and Baldwin, S. A. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem. J., 328: 739-743, 1997.
22. +-nucleoside cotransporter (hCNT1). Am, J. Physiol., 272: C707-C714, 1997.
23. +-dependent purine nucleoside transporter from human kidney: cloning and functional characterization. Am. J. Physiol., 273: F1058-F1065, 1997.
24. Belt, J. A., Marina, N. M., Phelps, D. A., and Crawford, C. R. Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul., 33: 235-252, 1993.
25. Vijayalakshmi, D., Dagnino, L., Belt, J. A., Gati, W. P., Cass, C. E., and Paterson, A. R. L1210/B23.1 cells express equilibrative, inhibitor-sensitive nucleoside transport activity and lack two parental nucleoside transport activities. J. Biol. Chem., 267: 16951-16956, 1992.
26. Boumah, C. E., Hogue, D. L., and Cass, C. E. Expression of high levels of nitrobenzylthioinosine-sensitive nucleoside transport in cultured human choriocarcinoma (BeWo) cells. Biochem. J., 288: 987-996, 1992.
27. Boleti, H., Coe, I. R., Baldwin, S. A., Young, J. D., and Cass, C. E. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology, 36: 1167-1179, 1997.
28. Belt, J. A., and Noel, L. D. Nucleoside transport in Walker 256 rat carcinosarcoma and S49 mouse lymphoma cells. Differences in sensitivity to nitrobenzylthioinosine and thiol reagents. Biochem. J., 232: 681-688, 1985.
29. Cass, C. E., Kolassa, N., Uehara, Y., Dahlig-Harley, E., Harley, E. R., and Paterson, A. R. Absence of binding sites for the transport inhibitor nitrobenzylthioinosine on nucleoside transport-deficient mouse lymphoma cells. Biochim. Biophys. Acta, 649: 769-777, 1981.
30. Crawford, C. R., Ng, C. Y., Noel, L. D., and Belt, J. A. Nucleoside transport in L1210 murine leukemia cells. Evidence for three transporters. J. Biol. Chem., 265: 9732-9736, 1990.
31. Crawford, C. R., Ng, C. Y., and Belt, J. A. Isolation and characterization of an L1210 cell line retaining the sodium-dependent carrier cif as its sole nucleoside transport activity. J. Biol. Chem., 265: 13730-13734, 1990.
32. Huang, Q. Q., Yao, S. Y., Ritzel, M. W., Paterson, A. R., Cass, C. E., and Young, J. D. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. J. Biol. Chem., 269: 17757-17760, 1994.
33. Crawford, C. R., Cass, C. E., Young, J. D., and Belt, J. A. Stable expression of a recombinant sodium-dependent, pyrimidine-selective nucleoside transporter (rCNT1) in a transport-deficient mouse leukemia cell line. Biochem. Cell Biol., in press, 1998.
34. Crawford, C. R., Ng, C. Y., Ullman, B., and Belt, J. A. Identification and reconstitution of the nucleoside transporter of CEM human leukemia cells. Biochim. Biophys. Acta, 1024: 289-297, 1990.
35. Ullman, B. Dideoxycytidine metabolism in wild type and mutant CEM cells deficient in nucleoside transport or deoxycytidine kinase. Adv. Exp. Med. Biol., 253B: 415-420, 1989.
36. Pattillo, R. A., and Gey, G. O. The establishment of a cell line of human hormonesynthesizing trophoblastic cells in vitro. Cancer Res., 28: 1231-1236, 1968.
37. Burres, N. S., and Cass, C. E. Density-dependent inhibition of expression of syncytiotrophoblastic markers by cultured human choriocarcinoma (BeWo) cells. J. Cell Physiol., 128: 375-382, 1986.
38. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst, 82: 1107-1112, 1990.
39. Rubenstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., and Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst., 82: 1113-1118, 1990.
40. Fang, X., Parkinson, F. E., Mowles, D. A., Young, J. D., and Cass, C. E. Functional characterization of a recombinant sodium-dependent nucleoside transporter with selectivity for pyrimidine nucleosides (cNT1rat) by transient expression in cultured mammalian cells. Biochem. J., 317: 457-465, 1996.
41. Mani, R. S., Hammond, J. R., Young, J. D., and Cass, C. E. Demonstration of high-affinity binding of nitrobenzylthioinosine and nitrobenzylthioinosine-sensitive undine transport in nuclear membranes of cultured human choriocarcinoma (BeWo) cells by functional reconstitution in proteoliposomes. J. Biol. Chem., in press, 1998.
42. Markwell, M. A. K., Hass, S. M., Tolbert, N. E., and Bieber, L. L. Protein determination in membrane and lipoprotein samples: manual and automated procedures. Methods Enzymol., 72: 296-303, 1981.
43. Hammond, J. R. Functional reconstitution of pharmacologically distinct subtypes of nucleoside transporters in liposomal membranes. J. Pharmacol. Exp. Ther., 271: 906-917, 1994.
44. Mimms, L. T., Zampighi, G., Nozaki, Y., Tanford, C., and Reynolds, J. A. Phospholipid vesicle formation and transmembrane protein incorporation using octylglucoside. Biochemistry, 20: 833-840, 1981.
45. Tse, C. M., and Young, J. D. Passive and carrier-mediated permeation of different nucleosides through the reconstituted nucleoside transporter. Biochim. Biophys. Acta, 985: 343-346, 1989.
46. Belt. J. A., Harper, E. H., Byl, J. A., and Noel, L. D. Sodium-dependent nucleoside transport inhuman myeloid leukemic cell lines and freshly isolated myeloblasts. Proc. Am. Assoc. Cancer Res., 33: 20, 1992.
47. Dagnino, L., and Paterson, A. R. Sodium-dependent and equilibrative nucleoside transport systems in L1210 mouse leukemia cells: effect of inhibitors of equilibrative systems on the content and retention of nucleosides. Cancer Res., 50: 6549-6553, 1990.
48. Cass, C. E., King, K. M., Montano, J. T., and Janowska-Wieczorek, A. A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin). Cancer Res., 52: 5879-5886, 1992.
49. White, J. C., Rathmell, J. P., and Capizzi, R. L. Membrane transport influences the rate of accumulation of 1-β-D-arabinofuranosylcytosine in human leukemia cells. J. Clin. Invest., 79: 380-387, 1987.
50. Wiley, J. S., Jones, S. P., Sawyer, W. H., and Paterson, A. R. 1-β-D-Arabinofuranosylcytosine influx and nucleoside transport sites in acute leukemia. J. Clin. Investig., 69: 479-489, 1982.
51. Gati, W. P., Paterson, A. R., Larratt, L. M., Turner, A. R., and Belch, A. R. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood, 90: 346-353, 1997.
52. Wiley, J. S., Woodruff, R. K., Jamieson, G. P., Firkin, F. C., and Sawyer, W. H. 1-β-D-Arabinofuranosylcytosine in the treatment of T-cell acute lymphoblasric leukemia. Aust. NZ J. Med., 17: 379-386, 1987.
53. Hoffman, J. Murine erythroleukemia cells resistant to periodate-oxidized adenosine have lowered levels of nucleoside transporter. Adv. Exp. Med. Biol., 309A: 443-446, 1991.
54. King, K. M., and Cass, C. E. Membrane transport of 2-chloro-2′-deoxyadenosine and 2-chloro-2′-arabinofluoro-2′-deoxyadenosine is required for cytotoxicity. Proc. Am. Assoc. Cancer Res., 35: A3436, 1994.
55. Cheson, B. D. Miscellaneous chemotherapeutic agents. In: V. T. Devita (ed.) Cancer: principles and practice of oncology, Ed. 5, Vol. 1, pp. 490-498. Philadelphia: Lippincott-Raven, 1997.
56. Allerheiligen, S., Johnson, R., and Hatcher, B. Gemcitabine pharmacokinetics are influenced by gender, body surface area, and duration of infusion. Proc. Am. Soc. Clin. Oncol., 13: A136, 1994.
57. Patil, S. D., and Unadkat, J. D. Sodium dependent nucleoside transport in the human intestinal brush border membrane. Am. J. Physiol. Gastro. Liver Physiol. 35: G1314-G1320, 1997.